207 related articles for article (PubMed ID: 23685570)
21. Synthesis, HPLC enantioresolution, and X-ray analysis of a new series of C5-methyl pyridazines as N-formyl peptide receptor (FPR) agonists.
Cilibrizzi A; Crocetti L; Giovannoni MP; Graziano A; Vergelli C; Bartolucci G; Soldani G; Quinn MT; Schepetkin IA; Faggi C
Chirality; 2013 Jul; 25(7):400-8. PubMed ID: 23744588
[TBL] [Abstract][Full Text] [Related]
22. The formyl peptide fMLF primes platelet activation and augments thrombus formation.
Salamah MF; Ravishankar D; Vaiyapuri R; Moraes LA; Patel K; Perretti M; Gibbins JM; Vaiyapuri S
J Thromb Haemost; 2019 Jul; 17(7):1120-1133. PubMed ID: 31033193
[TBL] [Abstract][Full Text] [Related]
23. Substituted Pyridazin-3(2 H)-ones as Highly Potent and Biased Formyl Peptide Receptor Agonists.
Deora GS; Qin CX; Vecchio EA; Debono AJ; Priebbenow DL; Brady RM; Beveridge J; Teguh SC; Deo M; May LT; Krippner G; Ritchie RH; Baell JB
J Med Chem; 2019 May; 62(10):5242-5248. PubMed ID: 31038950
[TBL] [Abstract][Full Text] [Related]
24. Synthesis, cytotoxic activity, and tubulin polymerization inhibitory activity of new pyrrol-2(3H)-ones and pyridazin-3(2H)-ones.
Abbas SH; Abuo-Rahma Gel-D; Abdel-Aziz M; Aly OM; Beshr EA; Gamal-Eldeen AM
Bioorg Chem; 2016 Jun; 66():46-62. PubMed ID: 27016713
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and antiproliferative effects of 5,6-disubstituted Pyridazin-3(2H)-ones designed as conformationally constrained combretastatin A-4 Analogues.
Elagawany M; Schmitt M; Ghiaty A; El-Etrawy ASh; Ibrahim MA; Bihel F; Sbardelotto AB; Pessoa C; Nguyen TL; Hamel E; Bourguignon JJ
Anticancer Agents Med Chem; 2013 Sep; 13(7):1133-40. PubMed ID: 23574386
[TBL] [Abstract][Full Text] [Related]
26. The pyrazolone originally reported to be a formyl peptide receptor (FPR) 2/ALX-selective agonist is instead an FPR1 and FPR2/ALX dual agonist.
Sogawa Y; Shimizugawa A; Ohyama T; Maeda H; Hirahara K
J Pharmacol Sci; 2009 Nov; 111(3):317-21. PubMed ID: 19926937
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, and biological evaluation of new series of pyrrol-2(3H)-one and pyridazin-3(2H)-one derivatives as tubulin polymerization inhibitors.
Abdelbaset MS; Abdelrahman MH; Bukhari SNA; Gouda AM; Youssif BGM; Abdel-Aziz M; Abuo-Rahma GEA
Bioorg Chem; 2021 Feb; 107():104522. PubMed ID: 33317838
[TBL] [Abstract][Full Text] [Related]
28. Mitocryptide-2: Identification of Its Minimum Structure for Specific Activation of FPR2-Possible Receptor Switching from FPR2 to FPR1 by Its Physiological C-terminal Cleavages.
Marutani T; Nishino K; Miyaji T; Kamada K; Ohura K; Kiso Y; Mukai H
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920954
[TBL] [Abstract][Full Text] [Related]
29. A non-peptide receptor inhibitor with selectivity for one of the neutrophil formyl peptide receptors, FPR 1.
Cevik-Aras H; Kalderén C; Jenmalm Jensen A; Oprea T; Dahlgren C; Forsman H
Biochem Pharmacol; 2012 Jun; 83(12):1655-62. PubMed ID: 22410002
[TBL] [Abstract][Full Text] [Related]
30. The formyl peptide receptors FPR1 and FPR2 as targets for inflammatory disorders: recent advances in the development of small-molecule agonists.
Yi X; Tran E; Odiba JO; Qin CX; Ritchie RH; Baell JB
Eur J Med Chem; 2024 Feb; 265():115989. PubMed ID: 38199163
[TBL] [Abstract][Full Text] [Related]
31. Upregulation of the N-formyl Peptide receptors in scleroderma fibroblasts fosters the switch to myofibroblasts.
Rossi FW; Napolitano F; Pesapane A; Mascolo M; Staibano S; Matucci-Cerinic M; Guiducci S; Ragno P; di Spigna G; Postiglione L; Marone G; Montuori N; de Paulis A
J Immunol; 2015 Jun; 194(11):5161-73. PubMed ID: 25917089
[TBL] [Abstract][Full Text] [Related]
32. Stable formyl peptide receptor agonists that activate the neutrophil NADPH-oxidase identified through screening of a compound library.
Forsman H; Kalderén C; Nordin A; Nordling E; Jensen AJ; Dahlgren C
Biochem Pharmacol; 2011 Feb; 81(3):402-11. PubMed ID: 21095183
[TBL] [Abstract][Full Text] [Related]
33. Functional expression of formyl peptide receptor family in human NK cells.
Kim SD; Kim JM; Jo SH; Lee HY; Lee SY; Shim JW; Seo SK; Yun J; Bae YS
J Immunol; 2009 Nov; 183(9):5511-7. PubMed ID: 19843937
[TBL] [Abstract][Full Text] [Related]
34. Unleashing the power of formyl peptide receptor 2 in cardiovascular disease.
Prevete N; Poto R; Marone G; Varricchi G
Cytokine; 2023 Sep; 169():156298. PubMed ID: 37454543
[TBL] [Abstract][Full Text] [Related]
35. The leukocyte chemotactic receptor FPR2, but not the closely related FPR1, is sensitive to cell-penetrating pepducins with amino acid sequences descending from the third intracellular receptor loop.
Forsman H; Bylund J; Oprea TI; Karlsson A; Boulay F; Rabiet MJ; Dahlgren C
Biochim Biophys Acta; 2013 Aug; 1833(8):1914-23. PubMed ID: 23562731
[TBL] [Abstract][Full Text] [Related]
36. The proteolytically stable peptidomimetic Pam-(Lys-βNSpe)6-NH2 selectively inhibits human neutrophil activation via formyl peptide receptor 2.
Skovbakke SL; Heegaard PM; Larsen CJ; Franzyk H; Forsman H; Dahlgren C
Biochem Pharmacol; 2015 Jan; 93(2):182-95. PubMed ID: 25462815
[TBL] [Abstract][Full Text] [Related]
37. The non-steroidal anti-inflammatory drug piroxicam blocks ligand binding to the formyl peptide receptor but not the formyl peptide receptor like 1.
Stenfeldt AL; Karlsson J; Wennerås C; Bylund J; Fu H; Dahlgren C
Biochem Pharmacol; 2007 Oct; 74(7):1050-6. PubMed ID: 17692291
[TBL] [Abstract][Full Text] [Related]
38. Non-peptide ligand binding to the formyl peptide receptor FPR2--A comparison to peptide ligand binding modes.
Stepniewski TM; Filipek S
Bioorg Med Chem; 2015 Jul; 23(14):4072-81. PubMed ID: 25882522
[TBL] [Abstract][Full Text] [Related]
39. Pyridinone Derivatives as Interesting Formyl Peptide Receptor (FPR) Agonists for the Treatment of Rheumatoid Arthritis.
Crocetti L; Vergelli C; Guerrini G; Giovannoni MP; Kirpotina LN; Khlebnikov AI; Ghelardini C; Di Cesare Mannelli L; Lucarini E; Schepetkin IA; Quinn MT
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770992
[TBL] [Abstract][Full Text] [Related]
40. Structural Determinants in the
Viklund M; Fredriksson J; Holdfeldt A; Lind S; Franzyk H; Dahlgren C; Sundqvist M; Forsman H
J Immunol; 2022 Apr; 208(7):1632-1641. PubMed ID: 35321878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
